Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

PAVmed (PAVM) Enterprise Value (2016 - 2026)

PAVmed has reported Enterprise Value over the past 6 years, most recently at -$13.2 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 118.65% year-over-year to -$13.2 million; the TTM value through Dec 2025 reached -$13.2 million, down 118.65%, while the annual FY2025 figure was -$13.2 million, 118.65% down from the prior year.
  • Enterprise Value for Q4 2025 was -$13.2 million at PAVmed, up from -$13.4 million in the prior quarter.
  • Over five years, Enterprise Value peaked at $39.9 million in Q3 2024 and troughed at -$59.5 million in Q4 2021.
  • A 5-year average of -$15.7 million and a median of -$13.5 million in 2025 define the central range for Enterprise Value.
  • Biggest five-year swings in Enterprise Value: crashed 203.22% in 2021 and later surged 559.87% in 2024.
  • Year by year, Enterprise Value stood at -$59.5 million in 2021, then skyrocketed by 67.85% to -$19.1 million in 2022, then soared by 153.19% to $10.2 million in 2023, then plummeted by 159.19% to -$6.0 million in 2024, then plummeted by 118.65% to -$13.2 million in 2025.
  • Business Quant data shows Enterprise Value for PAVM at -$13.2 million in Q4 2025, -$13.4 million in Q3 2025, and -$13.7 million in Q2 2025.